TICKERNERD
Menu
PTHSPTHSHealthcare · Biotechnology

PTHS Stock Forecast: Pelthos Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$27
+4.35% on the day

The 7 Wall Street analysts covering Pelthos Therapeutics, Inc. hold a median 12-month price target of $50 — +87.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 21 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$97.7M
Ticker Nerd rank
21 / 100
Median analyst target
$50
Analysts covering
7
Revenue$10.9M
Operating income−$13.1M
Net income−$10.2M
Free cash flow−$13.3M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+2.8%
1M
+2.7%
YTD
−14.1%
1Y
+18.3%
From 52W high
−28.9%
From 52W low
+46.3%
$18
$37
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PTHS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Pelthos Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
21 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
75
Momentum
69
Value
53
Quality
45
Accruals
38
Revisions
29
Volatility
25
Growth
8
Issuance
2

Size (75): Smaller than most of the companies we track.

Issuance (2): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PTHS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PTHS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50$60$70Oct 25Jan 26Apr 26Jul 26PTHSHigh $64Median $50Low $45

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
7 Buy0 Hold0 Sell
Low $45Median $50High $64

The green dot is the last close — the median target sits +87.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 Aug 2026OppenheimerMaintainsOutperform—
15 May 2026OppenheimerMaintainsOutperform—
1 Apr 2026Cantor FitzgeraldInitiatesOverweight—
20 Mar 2026OppenheimerMaintainsOutperform—
19 Mar 2026HC Wainwright & Co.ReiteratesBuy—
27 Feb 2026Piper SandlerInitiatesOverweight—
26 Feb 2026Roth CapitalMaintainsBuy—
26 Jan 2026OppenheimerMaintainsOutperform—
3 Dec 2025HC Wainwright & Co.InitiatesBuy—
3 Dec 2025Lake StreetInitiatesBuy—
25 Nov 2025Roth CapitalInitiatesBuy—
14 Nov 2025OppenheimerReiteratesOutperform—
2 Sept 2025OppenheimerInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PTHS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

PTHS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Aug 2026, Pelthos Therapeutics, Inc. returned +18.3% against +19.6% for the S&P 500, dividends included.

PTHS vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160Oct 25Jan 26Apr 26Jul 26PTHSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PTHS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Pelthos Therapeutics, Inc. (PTHS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.1×

Cheaper than 83% of US stocks

Price / sales
2.3×

Cheaper than 50% of US stocks

Price / book
2.4×

Cheaper than 41% of US stocks

EV / EBITDA
−3.2×

Cheaper than 75% of US stocks

Growth & margins
Revenue growth (YoY)
16.2%

Higher than 64% of US stocks

Earnings growth (YoY)
—
Gross margin
51.3%

Higher than 64% of US stocks

Operating margin
−101.4%

Higher than 13% of US stocks

Net margin
−199.5%

Higher than 2% of US stocks

Returns & dividend
Return on equity
−111.4%

Higher than 12% of US stocks

Return on assets
−50.0%

Higher than 8% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Pelthos Therapeutics, Inc. (PTHS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Pelthos Therapeutics, Inc. has a market value of $97.7M and an enterprise value of $146.6M.

  • Revenue in the twelve months to 31 Mar 2026: $27.7M. The latest quarter grew 16.2% year on year.

  • Net income over the same four quarters: −$51.6M, a −186.2% net margin.

  • Diluted earnings per share, trailing twelve months: $−20.64.

  • Free cash flow in the twelve months to 31 Mar 2026: −$43.3M.

  • Shares outstanding: 3.4M.

  • Trailing P/E: −1.1×; forward P/E: −4.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Pelthos Therapeutics, Inc. employs 92 people — $301K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

PTHS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PTHSPelthos Therapeutics, Inc.$97.7M
21
ATRAAtara Biotherapeutics, Inc.$97.4M
66
PYPDPolyPid Ltd.$97.3M
50
YARWYarrow Bioscience, Inc.$97.2M
51
BMEABiomea Fusion, Inc.$96.9M
50
FBIOFortress Biotech, Inc.$95.3M
79
CGTXCognition Therapeutics, Inc.$94.7M
39

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Pelthos Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PTHS news & analysis

Pelthos Therapeutics Q2 Earnings Call Highlights

MarketBeat · 14 Aug 2026neutral

Pelthos Therapeutics reported second-quarter revenue growth driven by increased prescriptions for its lead product ZELSUVMI after its July 2025 commercial launch. The company also discussed an accounting restatement concerning the fair-value measurement of convertible debt and outlined expected 2027 launches for its complementary products XEPI and XEGLYZE.

Why it matters — PTHS watchers would care because the update covers early commercial traction for ZELSUVMI, a convertible-debt accounting restatement, and the timeline for the company's next pipeline products.

Pelthos Therapeutics Inc. (PTHS) Q2 2026 Earnings Call Transcript

Seeking Alpha · 13 Aug 2026neutral

Pelthos Therapeutics Inc. held its Q2 2026 earnings call, and a transcript of the call was published by Seeking Alpha.

Why it matters — Investors and analysts monitoring PTHS can review management's commentary and financial results from the quarter.

Pelthos Therapeutics Inc. (PTHS) Reports Q2 Loss, Lags Revenue Estimates

Zacks Investment Research · 13 Aug 2026negative

Pelthos Therapeutics Inc. (PTHS) reported a Q2 loss of $6.62 per share, wider than the consensus estimate of a $3.02 loss and worse than the $5.38 per-share loss from the same quarter last year. Revenue also fell short of expectations.

Why it matters — The larger-than-expected quarterly loss and revenue miss signal that Pelthos Therapeutics is underperforming relative to analyst forecasts and its own year-ago results.

Pelthos Therapeutics Announces Second Quarter 2026 Financial Results

GlobeNewsWire · 13 Aug 2026positive

Pelthos Therapeutics announced its second quarter 2026 financial results. Zelsuvmi net product revenue grew 45% to $15.4 million in the second quarter of 2026, up from $10.7 million in the first quarter of 2026.

Why it matters — PTHS watchers would take note of the substantial quarter-over-quarter growth in Zelsuvmi net product revenue, a key indicator of the product's commercial performance.

FAQ

Frequently asked questions about PTHS stock

What is the PTHS stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Pelthos Therapeutics, Inc. have a median 12-month price target of $50, with estimates ranging from $45 to $64. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PTHS stock a buy right now?

Of the 7 analysts covering Pelthos Therapeutics, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Pelthos Therapeutics, Inc. 21 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PTHS?

As at 22 Aug 2026, Pelthos Therapeutics, Inc. ranks 21 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (75 of 100).

Will PTHS stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +87.8% from the last close, and Ticker Nerd's factor model ranks Pelthos Therapeutics, Inc. 21 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PTHS stock forecast for 2030?

No analyst covering Pelthos Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PTHS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $45 to $64 over the next 12 months.

How has PTHS stock performed over the past year?

Pelthos Therapeutics, Inc. returned +18.3% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Pelthos Therapeutics, Inc. do?

Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing innovative therapeutic products for high unmet patient needs.

What is the latest news on PTHS?

The most recent item we track (MarketBeat, 14 Aug 2026): "Pelthos Therapeutics Q2 Earnings Call Highlights". Pelthos Therapeutics reported second-quarter revenue growth driven by increased prescriptions for its lead product ZELSUVMI after its July 2025 commercial launch. The company also discussed an accounting restatement concerning the fair-value measurement of convertible debt and outlined expected 2027 launches for its complementary products XEPI and XEGLYZE.

Company

About Pelthos Therapeutics, Inc.

Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing innovative therapeutic products for high unmet patient needs. Its primary function is to develop and launch treatments like ZELSUVMI™, a novel therapeutic product for Molluscum contagiosum infections. Notably, Pelthos Therapeutics leverages its proprietary nitric oxide-based technology platform to address significant medical challenges. The company operates in the pharmaceutical sector, specifically targeting dermatological conditions. With a strong pipeline of potential product candidates, Pelthos aims to deliver impactful treatments to patients across various demographics. Its market significance lies in addressing unmet medical needs through pioneering therapeutic innovations.

CEO Mr. Scott M. Plesha · 92 employees · United States · https://pelthos.com